Edicotinib

TargetMol
Product Code: TAR-T15199
Supplier: TargetMol
CodeSizePrice
TAR-T15199-1mg1mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15199-2mg2mg£145.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15199-5mg5mg£195.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15199-1mL1 mL * 10 mM (in DMSO)£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15199-10mg10mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15199-25mg25mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15199-50mg50mg£539.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15199-100mg100mg£724.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Edicotinib is a brain penetrant and orally active inhibitor of the colony-stimulating factor-1 receptor (IC50: 3.2 nM). It shows less inhibitory effects on KIT and FLT3 (IC50: 20 nM and 190 nM). It has the potential for Alzheimer's disease and rheumatoid arthritis treatment.
CAS:
1142363-52-7
Formula:
C27H35N5O2
Molecular Weight:
461.61
Pathway:
Angiogenesis; Tyrosine Kinase/Adaptors
Purity:
0.9969
SMILES:
CC1(C)CCC(=CC1)c1nc(ccc1NC(=O)c1ncc([nH]1)C#N)C1CC(C)(C)OC(C)(C)C1
Target:
c-Fms; FLT; CSF-1R; c-Kit

References

1. Mancuso R, et al. CSF1R?inhibitor?JNJ-40346527?attenuates?microglial?proliferation?and?neurodegeneration?in?P301S?mice.Brain.?2019 Oct 1;142(10):3243-3264. 2. Genovese MC, et al. Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.J Rheumatol. 2015 Oct;42(10):1752-60.